Cytokinetics, Incorporated
CYTK
$74.13
$0.680.93%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -21.07% | 450.60% | 376.56% | 2,609.26% | 2,635.74% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -21.07% | 450.60% | 376.56% | 2,609.26% | 2,635.74% |
| Cost of Revenue | 3.70% | 15.82% | 22.57% | 22.52% | 18.85% |
| Gross Profit | -10.67% | 8.87% | -2.20% | 2.90% | 6.34% |
| SG&A Expenses | 53.04% | 46.05% | 32.03% | 29.32% | 34.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.58% | 27.56% | 26.24% | 25.06% | 24.25% |
| Operating Income | -29.42% | -13.19% | -14.17% | -9.21% | -8.08% |
| Income Before Tax | -47.45% | -34.84% | -33.15% | -30.45% | -11.19% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -47.45% | -34.84% | -33.15% | -30.45% | -11.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -47.45% | -34.84% | -33.15% | -30.45% | -11.19% |
| EBIT | -29.42% | -13.19% | -14.17% | -9.21% | -8.08% |
| EBITDA | -29.35% | -13.11% | -14.32% | -10.20% | -9.01% |
| EPS Basic | -41.60% | -29.45% | -24.35% | -17.08% | 4.66% |
| Normalized Basic EPS | -21.87% | -10.41% | -5.20% | 1.68% | 4.66% |
| EPS Diluted | -41.60% | -29.45% | -24.35% | -17.08% | 4.66% |
| Normalized Diluted EPS | -21.87% | -10.41% | -5.20% | 1.68% | 4.66% |
| Average Basic Shares Outstanding | 4.59% | 4.17% | 6.96% | 11.24% | 16.59% |
| Average Diluted Shares Outstanding | 4.59% | 4.17% | 6.96% | 11.24% | 16.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |